Apimeds Pharmaceuticals US I
13F holders, Q1 2026 (March 31)6holders −1
1new positions
3sold out
$1.79avg. 13F price*
At the end of Q1 2026, 6 institutions reported holding Apimeds Pharmaceuticals US I in their 13F filings, down 1 from Q4 2025. 1 opened new positions and 3 sold out. The largest holders were Hemenway Trust Co LLC ($490K), Vanguard Capital Management LLC ($172K) and Geode Capital Management, LLC ($72K).
- Company
- Apimeds Pharmaceuticals US I
- CUSIP
- 03771D102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $19K |
| Exits | 3 | $45K |
All 13F filers, Q4 2025 → Q1 2026: 19,318 shares bought and 27,238 shares sold, net −7,920 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Hemenway Trust Co LLC | 0.04% | No change | 274,000 | $490K |
| Vanguard Capital Management LLC | 0.00% | — | 95,929 | $172K |
| Geode Capital Management, LLC | 0.00% | Add +14.8% | 40,051 | $72K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 24,039 | $43K |
| Two Sigma Securities, LLC | 0.00% | New | 10,550 | $19K |
| UBS Group AG | 0.00% | Add +619.4% | 4,187 | $7K |
"% of holder's portfolio" is APIMEDS PHARMACEUTICALS US I's weight in each manager's 13F, not the share of Apimeds Pharmaceuticals US I the manager owns.